Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

New Pharmacokinetic Parameters of Imaging Substrates Quantified from Rat Liver Compartments

Catherine M. Pastor and Kim L.R. Brouwer
Drug Metabolism and Disposition January 2022, 50 (1) 58-64; DOI: https://doi.org/10.1124/dmd.121.000546
Catherine M. Pastor
Department of Radiology, University Hospital of Geneva, Switzerland (C.M.P.); Université de Paris, Centre de recherche sur l’inflammation, Inserm, U1149, CNRS, ERL8252, F-75006 Paris, France (C.M.P.); and Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (K.L.R.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim L.R. Brouwer
Department of Radiology, University Hospital of Geneva, Switzerland (C.M.P.); Université de Paris, Centre de recherche sur l’inflammation, Inserm, U1149, CNRS, ERL8252, F-75006 Paris, France (C.M.P.); and Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (K.L.R.B.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    (A) Perfused rat liver. Livers were perfused with a nonrecirculating system. QH was 30 ml/min. Cin values were constant during substrate perfusion: 200 µM (BOPTA) and 64 µM (MEB). Cout values were collected. Cbile and Qbile were measured in the common bile duct. A gamma counter placed over a right liver lobe recorded Cliver. (B) Liver concentrations measured by the counter. Livers (n = 6) were perfused with KHB solution + 200 µM [153Gd]DTPA, KHB, KHB + 200 µM [153Gd]BOPTA, and KHB. During BOPTA perfusion, DTPA concentrations were reported (***). (C) BOPTA and MEB transport by Oatp, Mrp2, and Mrp3. Cout included substrates that did not enter into hepatocytes (black points) and those that entered and returned to sinusoids (brown asterisks). Substrates eliminated into bile canaliculi (red points).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    (A) BOPTA and MEB liver extraction ratios. (B) Qbile measured during BOPTA and MEB perfusion. (C) Compartmental distribution of BOPTA in normal livers (n = 6) perfused with KHB solution + 200 µM [153Gd]BOPTA (45–75 minutes) (D) Compartmental distribution of MEB in normal livers (n = 6) perfused with KHB + 64 µM [99mTc]MEB (45–75 minutes). Liver concentrations (black symbols) were measured by a gamma counter. Concentrations in extracellular compartment (red symbols) were measured during the previous DTPA perfusion. Concentrations that originate from the bile canaliculi (blue symbols) and from hepatocyte volume (green symbols) were calculated.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    BOPTA (A) and MEB (B) hepatocyte influx rate (vin, left y-axis, black circles) and bile excretion rate (vbile) plus basolateral efflux rate (vef) (right y-axis, open circles) during accumulation period (45–75 minutes). Normal livers (n = 12) were perfused with KHB solution + 200 µM [153Gd]BOPTA or KHB + 64 µM [99mTc]MEB. Difference between vin and vbile + vef (gray area). (C) Accumulation of BOPTA and MEB hepatocyte concentrations (from 45 to 75 minutes of the experimental protocol). Accumulation was best described by a hinge function (red curve) defined by two lines with a gentle connection between them that intersected at T0 defined as the time when cellular excretion affects hepatocyte concentrations. (D) Bile concentrations measured 5 minutes after the start of substrate perfusion (time 50 minutes of the experimental protocol).

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    (A) BOPTA and MEB hepatocyte concentrations during the decay period (75–105 minutes) when livers were perfused with Krebs-Henseleit bicarbonate solution (rinse period). The decline in concentrations was best described by a two-phase decay (red curves). (B) BOPTA and MEB bile concentration decay.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    BOPTA (A) and MEB (B) CLbile (mlHC/min). CLbile was the slope of the linear regression between vbile and CHC during the accumulation and decay periods. BOPTA (C) and MEB (D) CLef (mlHC/min). CLef was the slope of linear regression between vef and CHC during the rinse period.

Tables

  • Figures
    • View popup
    TABLE 1

    Concentrations, transfer rates, and clearance values

    Imaging substratesP
    BOPTAMEB
    Concentrations (µM)
     End of perfusion period
      Cin20064
      Cout185 ± 35 ± 20.002
      Cliver574 ± 882,486 ± 3620.002
      CEC62 ± 2032 ± 70.004
      CHC78%441 ± 782,036 ± 3890.002
      CHC100%566 ± 992,610 ± 4980.002
      CBC72 ± 9417 ± 490.002
      Cbile16,791 ± 2,08597,017 ± 11,2890.002
    Transfer rates (nmol/min)
     End of perfusion period
      v464 ± 801,797 ± 610.002
      vin561 ± 811,819 ± 540.002
      vbile (nmol/min)390 ± 84990 ± 1660.002
      vef97 ± 722 ± 80.002
    Clearance parameters
     End of perfusion period
      CLH (mlKHB/min)2.3 ± 0.427.8 ± 0.90.002
      CLin (mlKHB/min)2.8 ± 0.428.1 ± 0.80.002
     Perfusion and rinse periods
      CLbile (mlHC/min)0.89 ± 0.250.47 ± 0.150.009
     Rinse period
      CLef (mlHC/min)0.18 ± 0.030.01 ± 0.010.002
      CLbile + CLef (mlHC/min)1.1 ± 0.30.5 ± 0.10.004
    Concentration ratios
      RHC/EC4 ± 233 ± 190.002
      Rbile/HC31 ± 645 ± 120.03
      RHV/HC0.006 ± 0.0010.0003 ± 0.00010.002
      Rbile/EC299 ± 1113218 ± 11090.002
    • CHC100% is CHC78% multiplied by 100/78. Substrate removal rate from sinusoids (v), hepatocyte influx rate (vin), bile excretion rate (vbile), and efflux rate back into sinusoids (vef). Hepatocyte-to-extracellular concentration ratio (RHC/EC) were measured at T0 in the absence of hepatocyte efflux. Bile-to-hepatocyte concentration ratio (Rbile/HC) was the slope of the relationship between CHC (x-axis) and Cbile (y-axis) during the perfusion and rinse periods. Hepatic vein–to-hepatocyte concentration ratio (RHV/HC) was the slope of the relationship between CHC (x-axis) and Cef (y-axis) during the rinse period. Bile-to-extracellular concentration ratio (Rbile/EC) was the maximal ability of transporters to concentrate substrates from the EC to bile compartment at the end of the perfusion period. CLH and CLin were expressed in ml of Krebs-Henseleit Bicarbonate (KHB) solution/min (mlKHB/min). CLef and CLbile were expressed in ml of hepatocytes (HC)/min (mlHC/min).

    • View popup
    TABLE 2

    BOPTA and MEB hepatocyte accumulation and decay

    Imaging substrateP
    BOPTAMEB
    Accumulation
     T0 (min)4.3 ± 1.03.9 ± 1.40.54
     L1 slope (µM/min)70 ± 15425 ± 820.004
     L2 slope (µM/min)10 ± 324 ± 60.004
    Decay
     Y0 (µM)588 ± 892731 ± 4990.002
     Y0,fast (µM)327 ± 611723 ± 3280.004
     kfast,HC (min−1)0.25 ± 0.190.21 ± 0.020.39
     T1/2fast (min)3.2 ± 1.63.3 ± 0.30.66
     Y0,slow (µM)235 ± 551008 ± 3080.004
     kslow,HC (min−1)0.044 ± 0.0070.016 ± 0.0040.004
     T1/2slow (min)16 ± 348 ± 170.004
     Rate constant ratio6.4 ± 3.414.5 ± 4.50.02
    • Hepatocyte accumulation was best described by a hinge function that included a first line L1 for time below T0 and a second line L2 for time higher than T0. T0 was the time when the two lines would intersect if there were no curve connecting them. Before T0, L1 slope characterized BOPTA and MEB influx by Oatps. After T0, accumulation rates decreased due to concomitant entry and efflux from hepatocytes. During decay, hepatocyte concentrations were best described with a two-phase decay model. The model was the sum of two components working simultaneously and defined by rate constants kfast,HC and kslow,HC and starting Y values (Y0,fast and Y0,slow). For each liver, Y0 is Y0,fast + Y0,slow.

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 50 (1)
Drug Metabolism and Disposition
Vol. 50, Issue 1
1 Jan 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
New Pharmacokinetic Parameters of Imaging Substrates Quantified from Rat Liver Compartments
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Drug Concentrations in Liver Compartments

Catherine M. Pastor and Kim L.R. Brouwer
Drug Metabolism and Disposition January 1, 2022, 50 (1) 58-64; DOI: https://doi.org/10.1124/dmd.121.000546

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Drug Concentrations in Liver Compartments

Catherine M. Pastor and Kim L.R. Brouwer
Drug Metabolism and Disposition January 1, 2022, 50 (1) 58-64; DOI: https://doi.org/10.1124/dmd.121.000546
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics